Thursday, 15th March Eradicate Cancer 2018

• Richard Boyd, Alan Trounson Introduction of Commonwealth Government Minister for Health. - Richard Boyd

• The role of immune checkpoint blockade in the cure of HIV infection - Sharon Lewin
• Opening of Conference - Honourable Greg Hunt, Minister for Health of the Australian Commonwealth Government - Greg Hunt
• The anti-cancer immunotherapy landscape - Irv Weissman
• Tumour antigen-directed anti-cancer therapy in the era of checkpoint blockade - Jonathan Cebon

• CAR’s and armoured CARs - Renier Brentjens
• CAR-T cell therapy for the GD2 tumour target - Michael Brown
• Pre-clinical assessment of EphA2-directed CAR-T cell adoptive therapy for paediatric solid tumours - Kenneth Hsu
• Development of dual specific CAR-T cells – a one-two anti-cancer punch - Richard Boyd
• Multi-pronged approaches to augmenting CAR T cell therapy for solid tumours - Joseph A Trapani

12:15-12:30

GE HEALTHCARE - Aaron Dulgar-Tulloch, Director of the GE BridGE facility at the CCRM in Toronto Smart, Closed & Connected Solutions for Cell Therapy Manufacturing

Lunch and Learn Session:

Thursday 15th and Friday 16th March

Time: 12.30-12.40pm

Where: Booth #2

ATCC "Lunch and Learn session "

Topic: How should you pick and choose cell lines for your cancer research.

More info? https://lifescience.invitro.com.au/l/eradicate-cancer/

• Transposon CAR T-cells for Relapsed Leukaemia and Lymphoma - Kenneth Micklethwaite
• Genome editing provides solution for cell therapy safety and immune tolerance: a guide for a One4All pluripotent cell line - Andras Nagy

• Adoptive T cell Therapy:  targeting solid tumors through antigen discovery - Cassian Yee
• The potential therapeutic role of personalized neoantigen cancer vaccines - Bruce Robinson
• Unconventional T cell targets for cancer Immunotherapy - Dale Godfrey
• Molecular sculpturing of scFv’s and their payloads to optimise anti-cancer targeting - Peter Hudson
• Putative neoantigens predicted from frame-shift mutations of malignant pleural mesothelioma - Tian Mun Chee

• Revealing the immune changes that associate with breast cancer risk to develop prophylactic immune therapies - Kara Britt
• Targeting RAS/MAPK signalling to enhance tumour immunogenicity - Paul Beavis
• IL-18 critically drives multiple myeloma progression by generating an immunosuppressive microenvironment. - Mark Smyth
• Mass cytometric analysis of life and death decisions in blood cancer (cells) - Daniel Gray
• Integrin-linked kinase expression in myeloid cells promotes colon tumorigenesis - Afsar U. Ahmed
• Adoptive transfer of genetically engineered monocytes for the tumour targeted delivery of IFN-alpha - Roberta Mazzieri

Co-presented by the Eradicate Cancer with Immunotherapy  Conferenceand the Melbourne Immunotherapy Network (MiN)
Convenor - Grant McArthur, Peter MacCallum Cancer Centre
Co-convenor  - Alan Trounson Cartherics and the Hudson Institute for Medical Research

• Melt electrospun 3 D lattices for the clinical scale expansion of immunomodulatory cells including human regulatory T cells (Tregs)   - Simon C Barry
• TCR silencing with shRNA as a foundation for a bank of allogeneic CAR19 T-cells generated by single-step genetic modification using the piggyBac transposase - David C Bishop
• Working towards personalized immunotherapy in breast cancer - Natasha Brockwell
• Expression of cancer stem cell CD44 in patients with chronic gastritis, pre-cancerous and gastric cancer - Arnajak Mr. Dechsupa
• New strategies to improve the efficacy of personalized cancer immunotherapy - Riccardo Dolcetti
• Constitutive activation of YAP/TAZ disrupts pancreatic homeostasis - David Eisenbarth
• Rational design of cancer vaccines by targeting dendritic cells - Filipp Esselborn
• SAR131675 a VEGFR-3 specific inhibitor reduces tumour growth in a mouse model of colorectal cancer liver metastases by modulating the immune system. - George Kastrappis
• Defining the Scheduling and Immunological Parameters underlying the Efficacy of Neoadjuvant Immunotherapy - Jing Liu
• Is Australia "cell and gene therapy ready"? A vision for a world class cell and gene therapy industry in Australia - Tim Oldham
• Tissue-specific differences in the tumour microenvironment and immunotherapeutic responses - Amanda J Oliver
• Expression and polymorphisms of MDM2 in gastric cancer correlate with clinicopathological characteristics - Washiraya Mrs Polkang
•  Mechanisms of resistance of tumors to adoptive cell transfer and vaccination - Tinaz Samiei
• Targeting of multiple determinants on solid tumors using chimeric antigen receptor T cells - Roland Shu
• Association of MDM2 Protein Expression and Histopathological Grading of Cholangiocarcinoma in Northeast Thailand - Pakorn Tangjanyatham
• Expression of CD44 cancer stem cell and MDM2  in Cholangiocarcinoma Correlates with Poor Clinicopathological characteristics - Taweesak Asst.Prof. Tongtawee
• Optimising T-cell transduction and expansion conditions for CAR T-cell therapy in solid cancers - Nga Truong
• Inhibition of the renin-angiotensin system reduces tumour growth and modulates macrophage activation in a mouse model of colorectal cancer liver metastases. - Katrina A Walsh
• Imaging Activated Platelets in Cancer- An Avenue For Early Cancer Detection and Targeted Therapy. - May Lin Yap
• PD-L1 expression is a prognostic factor in subgroups of gastric cancer patients stratified according to their levels of CD8 and FOXP3 immune markers - Le Ying
• Fibroblast activation protein (FAP) is overexpressed in glioblastoma brain tumours and represents a potential target for immunotherapy - Lisa M Ebert
• Smart, Closed & Connected Solutions for Cell Therapy Production - Aaron Dulgar-Tulloch
• Rational Development for Cell and Gene Therapy Manufacturing - Aaron Dulgar-Tulloch
• An Efficient NGS Workflow for Liquid Biopsy Research Using a Comprehensive Assay Panel to Assess Cell-Free Total Nucleic Acid - Bansi Sanghvi